Tiago Fauth
Stock Analyst at Wells Fargo
(3.14)
# 2,394
Out of 5,182 analysts
145
Total ratings
43.12%
Success rate
1.74%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $153.40 | +41.46% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $7.39 | +143.57% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $578.54 | -28.44% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $2.74 | +264.96% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $73.01 | -0.01% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $38.71 | -19.92% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $339.41 | +16.38% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $24.57 | +164.55% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $77.93 | -2.48% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $6.07 | +15.32% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $29.95 | +237.23% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.30 | +130.77% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $11.55 | +125.11% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.46 | +17.61% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $70.52 | +6.35% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $249.84 | -64.38% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $15.19 | +235.75% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $55.47 | +116.33% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $26.55 | -84.93% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.15 | +344.44% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $67.80 | +342.48% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $9.14 | +184.46% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.76 | +644.68% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $40.85 | +98.29% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $400 | $4.27 | +9,267.68% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.70 | +723.53% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.62 | +2,005.26% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $45.86 | -36.76% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.47 | +787.37% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $3.39 | +283.48% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.14 | +75.44% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $828.35 | -58.95% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $350.95 | -26.20% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $153.40
Upside: +41.46%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $7.39
Upside: +143.57%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $578.54
Upside: -28.44%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.74
Upside: +264.96%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $73.01
Upside: -0.01%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $38.71
Upside: -19.92%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $339.41
Upside: +16.38%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $24.57
Upside: +164.55%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $77.93
Upside: -2.48%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $6.07
Upside: +15.32%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $29.95
Upside: +237.23%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.30
Upside: +130.77%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $11.55
Upside: +125.11%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.46
Upside: +17.61%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $70.52
Upside: +6.35%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $249.84
Upside: -64.38%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $15.19
Upside: +235.75%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $55.47
Upside: +116.33%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $26.55
Upside: -84.93%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.15
Upside: +344.44%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $67.80
Upside: +342.48%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $9.14
Upside: +184.46%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.76
Upside: +644.68%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $40.85
Upside: +98.29%
Mar 24, 2023
Reiterates: Neutral
Price Target: $400
Current: $4.27
Upside: +9,267.68%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.70
Upside: +723.53%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.62
Upside: +2,005.26%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $45.86
Upside: -36.76%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.47
Upside: +787.37%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $3.39
Upside: +283.48%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.14
Upside: +75.44%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $828.35
Upside: -58.95%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $350.95
Upside: -26.20%